Zhong Dong-Xiang, Zhang Yuan, Jin Qi, Zhang Xiao-Chun, Zhang Feng, Chen Dan-Dan, Guan Li-Hua, Zhou Da-Xin, Ge Jun-Bo
Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
Pulm Circ. 2021 Oct 12;11(4):20458940211051292. doi: 10.1177/20458940211051292. eCollection 2021 Oct-Dec.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important and major player in the pathophysiology of hypercholesterolemia and atherosclerosis. Recently, PCSK9 has been implicated in the pathogenesis of inflammatory diseases. Whether PCSK9 is involved in idiopathic pulmonary arterial hypertension (IPAH) remains unclear. This study aimed to investigate the relationship between PCSK9 and IPAH. Serum PCSK9, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-1 β (IL-1β), and monocyte chemotactic protein-1 (MCP-1) were measured by enzyme linked immunosorbent assay. Transthoracic echocardiography was performed among 40 IPAH patients and 20 control subjects. Hemodynamic data were collected via right heart catheterization in patients with IPAH. Serum PCSK9, TNF-α, IL-6, IL-1β, and MCP-1 levels were significantly higher in IPAH patients than in control subjects (p < 0.001). Among enrolled IPAH patients, PCSK9 levels were higher in WHO-FC III/IV patients compared with those in WHO-FC I/II (p < 0.05), and were positively correlated with TNF-α, IL-6, MCP-1, N-Terminal pro-brain natriuretic peptide, pulmonary arterial systolic pressure (r = 0.653, p < 0.001), pulmonary arterial diastolic pressure (r = 0.466, p = 0.002), mean pulmonary arterial pressure (mPAP, r = 0.730, <0.001), pulmonary vascular resistance (r = 0.488, p = 0.001), and right ventricle diameter (r = 0.563, p < 0.001). In multiple regression analysis, mPAP was strongly associated with serum PCSK9 (β = 0.694, p < 0.001), independent of other variables. Receiver operating characteristic curve analysis showed the optimal cutoff value of serum PCSK9 concentration for predicting IPAH was 90.67 ng/ml, with a sensitivity of 90.0% and a specificity of 85.0%. In conclusion, IPAH patients had elevated serum PCSK9 levels which correlated the presence and severity of pulmonary hypertension. PCSK9 may be a novel potential therapeutic target.
前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)是高胆固醇血症和动脉粥样硬化病理生理学中的一个重要且主要的因素。最近,PCSK9已被认为与炎症性疾病的发病机制有关。PCSK9是否参与特发性肺动脉高压(IPAH)仍不清楚。本研究旨在探讨PCSK9与IPAH之间的关系。通过酶联免疫吸附测定法检测血清PCSK9、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)和单核细胞趋化蛋白-1(MCP-1)。对40例IPAH患者和20例对照者进行经胸超声心动图检查。通过右心导管插入术收集IPAH患者的血流动力学数据。IPAH患者的血清PCSK9、TNF-α、IL-6、IL-1β和MCP-1水平显著高于对照者(p<0.001)。在纳入的IPAH患者中,世界卫生组织功能分级(WHO-FC)III/IV级患者的PCSK9水平高于WHO-FC I/II级患者(p<0.05),且与TNF-α、IL-6、MCP-1、N末端脑钠肽前体、肺动脉收缩压(r = 0.653,p<0.001)、肺动脉舒张压(r = 0.466,p = 0.002)、平均肺动脉压(mPAP,r = 0.730,<0.001)、肺血管阻力(r = 0.488,p = 0.001)和右心室直径(r = 0.563,p<0.001)呈正相关。在多元回归分析中,mPAP与血清PCSK9密切相关(β = 0.694,p<0.001),独立于其他变量。受试者工作特征曲线分析显示,预测IPAH的血清PCSK9浓度最佳截断值为90.67 ng/ml,敏感性为90.0%,特异性为85.0%。总之,IPAH患者血清PCSK9水平升高,这与肺动脉高压的存在和严重程度相关。PCSK9可能是一个新的潜在治疗靶点。